<table id="table6" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><caption>Table 6. Drugs That Should Not Be Coadministered With RESCRIPTOR</caption>
<col align="left" width="40%"></col>
<col align="left" width="60%"></col>
<thead>
<tr><th stylecode="Lrule">Drug Class: Drug Name</th><th stylecode="Lrule Rrule">Clinical Comment</th></tr>
</thead>
<tbody>
<tr><td stylecode="Lrule Botrule">Anticonvulsant agents: <br/>  phenytoin, phenobarbital, carbamazepine</td><td stylecode="Lrule Botrule Rrule">May lead to loss of virologic response and possible resistance to RESCRIPTOR or to the class of non-nucleoside reverse transcriptase inhibitors.</td></tr>
<tr><td stylecode="Lrule Botrule">Antihistamines: <br/>  astemizole, terfenadine</td><td stylecode="Lrule Botrule Rrule">CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.</td></tr>
<tr><td stylecode="Lrule Botrule">Antimycobacterials: <br/>  rifabutin,<footnote id="Footnote9_9">See <content stylecode="Bold"><linkhtml href="#clinical_pharmacology">CLINICAL PHARMACOLOGY</linkhtml></content> for magnitude of interaction, Tables 1 and 2.</footnote> rifampin<footnoteref idref="Footnote9_9"></footnoteref></td><td stylecode="Lrule Botrule Rrule">May lead to loss of virologic response and possible resistance to RESCRIPTOR or to the class of non-nucleoside reverse transcriptase inhibitors or other coadministered antiviral agents.</td></tr>
<tr><td stylecode="Lrule Botrule" valign="top">Ergot Derivatives:<br/>   dihydroergotamine, ergonovine, ergotamine, methylergonovine</td><td stylecode="Lrule Botrule Rrule">CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.</td></tr>
<tr><td stylecode="Lrule Botrule">GI motility agent:<br/>  cisapride</td><td stylecode="Lrule Botrule Rrule">CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.</td></tr>
<tr><td stylecode="Lrule Botrule">Herbal Products:<br/>  St. John's wort (hypericum perforatum)</td><td stylecode="Lrule Botrule Rrule">May lead to loss of virologic response and possible resistance to RESCRIPTOR or to the class of non-nucleoside reverse transcriptase inhibitors.</td></tr>
<tr><td stylecode="Lrule Botrule">HMG-CoA reductase inhibitors:<br/>  lovastatin, simvastatin</td><td stylecode="Lrule Botrule Rrule">Potential for serious reactions such as risk of myopathy including rhabdomyolysis.</td></tr>
<tr><td stylecode="Lrule Botrule">Neuroleptic:<br/>  pimozide</td><td stylecode="Lrule Botrule Rrule">CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.</td></tr>
<tr><td stylecode="Lrule Botrule">Sedative/hypnotics: <br/>  alprazolam, midazolam, triazolam</td><td stylecode="Lrule Botrule Rrule">CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.</td></tr>
</tbody>
</table>